Seoul – September 20, 2026 -- NAVER D2SF, the in-house corporate venture arm of NAVER, has joined a $10 million Series A2 bridge round for Silicon Valley-based precision medicine company ImpriMed, backing its push toward U.S. regulatory clearance and Asian market expansion.

Seoul – September 18, 2026 -- Hanwha Power has secured Approval in Principle (AiP) from the American Bureau of Shipping for a 22,000-cubic-meter LNG bunkering vessel concept design, the company announced on September 15 at GASTECH 2026 in Bangkok, Thailand.

London – September 17, 2026 -- Echion Technologies and Energy Tech Solution (ETS) have signed a memorandum of understanding to jointly develop batteries built on Echion's XNO® niobium-based anode material, targeting mining, rail, maritime and datacenter customers that require high-intensity power performance.

Toronto – September 17, 2026 -- Global Battery Materials Corp. (GBM) has signed a non-binding Letter of Intent with South Korean battery manufacturer LiBEST to evaluate and potentially commercially supply natural graphite, coated spherical purified graphite (CSPG), and other anode materials sourced and processed entirely outside China.

Seoul, South Korea – September 17, 2026 -- Yuyu Pharma has completed an 869-kilowatt (kW) solar installation at its Korean manufacturing facility, lifting total on-site solar capacity to approximately 1 megawatt (MW) and covering more than 30% of the plant's electricity needs.

Seoul – September 16, 2026 -- Johnson & Johnson reported that its RYBREVANT (amivantamab-vmjw) plus chemotherapy combination extended median overall survival to 34.3 months in patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer, compared with 27.9 months for chemotherapy alone, according to final data from the Phase 3 PAPILLON study.

Seoul – September 16, 2026 -- Hyundai Motor Group has put its "Data Flywheel" system into full operation, converting real-world driving data from an annual fleet of 7 million vehicles sold across the Group into continuous AI training and validation cycles for autonomous driving technology.

Seoul – September 12, 2026 -- SystImmune, Inc. announced that new global Phase 1 data support 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose for iza-bren (izalontamab brengitecan), a bispecific EGFRxHER3 antibody drug conjugate, in previously treated EGFR-mutated metastatic non-small cell lung cancer (NSCLC).

Seoul -- September 9, 2026 -- MegazoneCloud has begun system development on 'Hanmi Q-Agent,' an AI agent designed to cut Hanmi Pharmaceutical's quality assurance document workload by more than 40%, with build work starting September 7.

Seoul, South Korea – September 15, 2026 -- HD Hyundai Heavy Industries will invest a combined KRW 1.0722 trillion to build a new land-based power generation engine plant and a dedicated small modular reactor (SMR) equipment facility, both in Ulsan, as it races to capture surging power demand from AI data centers.